Restless Legs Syndrome: Neurochemistry and Therapy
Seminars in Neurology · 01.06.2025 · 45 (03) · 368-382
DOI: 10.1055/a-2538-3300 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Neurology, erschienen am 01.06.2025. Verfasst von David Anguizola und 3 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Europeo del Sueño, Panamá, Panamá. Hauptthemen laut MEDLINE: Restless Legs Syndrome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 110 Literaturangaben.
Abstract (Originalsprache)
Restless legs syndrome (RLS) is a complex sensorimotor disorder characterized by disturbances in key neurochemical pathways, including dopaminergic, glutamatergic, and adenosinergic systems. This review provides an overview of the current knowledge on RLS, including its clinical features and diagnosis, pathophysiology, and treatment (non-pharmacological and pharmacological). We examine the association between RLS and neurological disorders, genetic predispositions, and brain iron deficiency. Emerging therapies targeting glutamate and adenosine receptors, alongside established dopamine agonists and α2δ ligands, offer promising avenues for treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Instituto Europeo del Sueño, Panamá, Panamá.
- Sleep Research Institute, Madrid, Spain.
Zitieren
APA
Anguizola, D., Garcia Aragón, A., Moncada, B., & Garcia-Borreguero, D. (2025). Restless Legs Syndrome: Neurochemistry and Therapy. Seminars in Neurology, 45(03), 368-382. https://doi.org/10.1055/a-2538-3300
Vancouver
Anguizola D, Garcia Aragón A, Moncada B, Garcia-Borreguero D. Restless Legs Syndrome: Neurochemistry and Therapy. Seminars in Neurology. 2025;45(03):368-382. doi:10.1055/a-2538-3300
BibTeX
@article{Anguizola2025,
author = {Anguizola, David and Garcia Aragón, Alba and Moncada, Brian and Garcia-Borreguero, Diego},
title = {Restless Legs Syndrome: Neurochemistry and Therapy},
journal = {Seminars in Neurology},
year = {2025},
volume = {45},
number = {03},
pages = {368--382},
doi = {10.1055/a-2538-3300}
}
EUVIMED